Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio
announced a collaboration to potentially identify and develop
blood-based biomarkers for tau pathology in the brain and to
potentially clinically advance and potentially commercialize new
tests for tau pathology in Alzheimer’s disease (AD). The
development of tau-specific blood-based biomarkers that can measure
a patient’s tau burden could provide critical insights into the
underlying pathological processes of AD and may help advance the
development of a new generation of therapies impacting tau
pathology.
Through this collaboration, the companies will work to identify
new blood-based biomarkers and advance known blood-based biomarkers
for tau pathology in AD. The collaboration aims to develop and
clinically advance new tools that measure brain tau pathology to
potentially stratify patients or monitor treatment response in AD
clinical trials. The collaboration has the potential to advance
tau-specific blood-based biomarkers and diagnostic tools that could
be used not only in clinical trials, but also in clinical practice
to enable adoption of future therapies impacting tau pathology.
“Stratifying and monitoring patients for tau pathology is a
growing need for the next generation of Alzheimer's therapies, such
as our pipeline of investigational tau-targeting therapies,
including tau-directed ASO,” said Jane Grogan, Ph.D., Head of
Research at Biogen. “Through this collaboration, we plan to
leverage our deep scientific expertise in the development and use
of biomarkers, combined with our partners’ capabilities in
diagnostics, to potentially accelerate the development timeline for
blood-based diagnostics that can measure a patient’s levels of tau
pathology.”
“Collaborative efforts between Biogen, Beckman Coulter and
Fujirebio combine the strength of leading edge biomarker
development with innovative potential treatments focused on the
tauopathy aspect of neurodegeneration, driving us closer to
effective solutions,” said Kathleen Orland, Senior Vice President,
General Manager, Chemistry, and Immunoassay for Beckman Coulter
Diagnostics. “Ensuring high quality neurological tests are broadly
available through our global installed-base of analyzers, this
collaboration with Biogen and Fujirebio underscores our commitment
to working with leaders in neurodegenerative disease areas to bring
fully automated, high throughput, blood-based Alzheimer's disease
testing to the millions of patients who suffer from dementia
worldwide.”
“Blood-based biomarkers for tau pathology could advance the
development and implementation of disease-modifying therapies for
neurodegenerative disorders such as AD,” said Monte Wiltse,
President & CEO of Fujirebio Diagnostics, Inc. “This
partnership will further help us accelerate our efforts to develop
novel neurodegenerative disease diagnostics and deliver them to
laboratories and clinicians around the world via our global
diagnostics partners, addressing the unmet medical need for
blood-based biomarkers.”
Under the terms of the collaboration, Biogen will provide
Alzheimer's clinical study data and expertise in biomarker research
to prioritize markers for tau pathology. Fujirebio and Beckman
Coulter will be responsible for providing diagnostic development,
manufacturing and commercialization.
About BiogenFounded in 1978, Biogen is a
leading biotechnology company that pioneers innovative science to
deliver new medicines to transform patients’ lives and to create
value for shareholders and our communities. We apply deep
understanding of human biology and leverage different modalities to
advance first-in-class treatments or therapies that deliver
superior outcomes. Our approach is to take bold risks, balanced
with return on investment to deliver long-term growth.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social
media - Facebook, LinkedIn, X, YouTube.
About Beckman Coulter. Inc. A global leader in
advanced diagnostics, Beckman Coulter has challenged convention to
elevate the diagnostic laboratory’s role in improving patient
health for more than 80 years. Our mission is to Relentlessly
Reimagine Healthcare, One Diagnosis at a Time – and we do this by
applying the power of science, technology and the passion and
creativity of our teams. Our diagnostic solutions are used in
complex clinical testing, and are found in hospitals, reference
laboratories and physician office settings around the globe. We
exist to deliver smarter, faster diagnostic solutions that move the
needle forward from what’s now to what’s next. We do this by
accelerating care with an extensive clinical menu, scalable lab
automation technologies, insightful clinical informatics, and lab
performance services. Headquartered in Brea, Calif., Beckman
Coulter has more than 11,000 global team members. 2024-13330.
Follow and connect with Beckman Coulter
via LinkedIn, X, and Facebook
About Fujirebio Fujirebio, a member of H.U.
Group Holdings Inc., is a global leader in the field of
high-quality in vitro diagnostics (IVD) testing. It has more than
50 years’ accumulated experience in the conception, development,
production, and worldwide commercialization of robust IVD products.
Fujirebio supplies new technology and novel diagnostic markers to
the global Diagnostics industry through material supply, contract
development and manufacturing.
Fujirebio was the first company to develop and market CSF
biomarkers under the Innogenetics brand over 25 years ago.
Fujirebio remains the only company with such a comprehensive
line-up of manual and fully automated neurodegenerative disease
assays and consistently partners with organizations and clinical
experts across the world to develop new pathways for earlier,
easier and more complete neurodegenerative diagnostic tools. More
information can be found at www.fujirebio.com/alzheimer.
Biogen Safe Harbor
This press release contains forward-looking statements, relating
to: our strategy and plans; potential of, and expectations for, our
commercial business and pipeline programs; capital allocation and
investment strategy; clinical development programs, clinical
trials, and data readouts and presentations; the potential for
blood based AD biomarker tests; regulatory discussions,
submissions, filings, and approvals; the potential benefits,
safety, and efficacy of our and our collaboration with Beckman
Coulter Diagnostics and Fujirebio;. These forward-looking
statements may be accompanied by such words as “aim,” “anticipate,”
“believe,” “could,” “estimate,” “expect,” “forecast,” “goal,”
“intend,” “may,” “plan,” “potential,” “possible,” “prospect,”
“will,” “would,” and other words and terms of similar meaning. Drug
development and commercialization involve a high degree of risk,
and only a small number of research and development programs result
in commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these
statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including: our dependence on sales from our
products; uncertainty of long-term success in developing,
licensing, or acquiring other product candidates or additional
indications for existing products; failure to compete effectively;
failure to successfully execute or realize the anticipated benefits
of our strategic and growth initiatives; difficulties in obtaining
and maintaining adequate coverage, pricing, and reimbursement for
our products; our dependence on collaborators and other third
parties for the development, regulatory approval, and
commercialization of products and other aspects of our business,
which are outside of our full control; risks associated with
current and potential future healthcare reforms; risks related to
commercialization of biosimilars; failure to obtain, protect, and
enforce our data, intellectual property, and other proprietary
rights and the risks and uncertainties relating to intellectual
property claims and challenges; the risk that positive results in a
clinical trial may not be replicated in subsequent or confirmatory
trials or success in early stage clinical trials may not be
predictive of results in later stage or large scale clinical trials
or trials in other potential indications; risks associated with
clinical trials, including our ability to adequately manage
clinical activities, unexpected concerns that may arise from
additional data or analysis obtained during clinical trials,
regulatory authorities may require additional information or
further studies, or may fail to approve or may delay approval of
our drug candidates; the occurrence of adverse safety events,
restrictions on use with our products, or product liability claims;
risks relating to technology failures or breaches; problems with
our manufacturing processes; risks relating to management,
personnel and other organizational changes, including attracting
and retaining personnel; failure to comply with legal and
regulatory requirements; the risks of doing business
internationally, including currency exchange rate fluctuations;
risks relating to investment in our manufacturing capacity; risks
relating to the distribution and sale by third parties of
counterfeit or unfit versions of our products; risks relating to
the use of social media and artificial intelligence based software
for our business; results of operations, and financial condition;
fluctuations in our operating results; risks related to investment
in properties; risks relating to access to capital and credit
markets; risks related to indebtedness; the market, interest, and
credit risks associated with our investment portfolio; risks
relating to share repurchase programs; change in control provisions
in certain of our collaboration agreements; fluctuations in our
effective tax rate; environmental risks; and any other risks and
uncertainties that are described in other reports we have filed
with the U.S. Securities and Exchange Commission.
These statements speak only as of the date of this press
release. We do not undertake any obligation to publicly update any
forward-looking statements.
MEDIA
CONTACT(S):BiogenJack Cox+ 1 781 464
3260public.affairs@biogen.comBeckman Coulter
DiagnosticsJeff Tarmy+ 1 617 467
7537jtarmy@beckman.comH.U. Group
Holdings/FujirebioKazumi Kobayashi+ 81 3 6279
0884pr@hugp.com |
INVESTOR
CONTACT(S):BiogenChuck Triano+1 781 464
2442IR@biogen.com H.U. Group
Holdings/FujirebioHisashi Yamakawa+ 81 3 6279
0926ir@hugp.com |
Biogen (NASDAQ:BIIB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Biogen (NASDAQ:BIIB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024